A 62-year-old woman comes to the clinic reporting intermittent vaginal spotting for the past month. She went through menopause at age 50. Her medical history is notable for estrogen receptor-positive breast cancer diagnosed three years ago, which was treated with lumpectomy, radiation therapy, and ongoing tamoxifen therapy. Vital signs are within normal limits. Pelvic examination demonstrates a normal-appearing vulva, thin vaginal mucosa, and a small amount of dark red blood in the vaginal vault. The cervix has no visible lesions. A transvaginal ultrasound reveals a heterogeneous endometrial stripe of 14 mm. Which of the following is the most appropriate next step in management?
- Endometrial biopsyAnswer
- BDiscontinuation of tamoxifen and repeat ultrasonography
- CCervical cytology with human papillomavirus co-testing
- DMeasurement of serum CA-125 level
- EReassurance and routine annual follow-up
Answer
Endometrial biopsy
The correct response is an endometrial biopsy. This patient presents with postmenopausal bleeding and a significantly thickened endometrial stripe (14 mm) on transvaginal ultrasound. Postmenopausal bleeding is the cardinal symptom of endometrial cancer. Her risk is substantially elevated due to her use of tamoxifen, a selective estrogen receptor modulator (SERM) that exerts anti-estrogenic effects on breast tissue but pro-estrogenic effects on the endometrium. Current guidelines mandate that any postmenopausal woman with vaginal bleeding and an endometrial thickness >4 mm undergo direct histologic evaluation via an endometrial biopsy to rule out endometrial hyperplasia or carcinoma.
Step-by-Step Solution
Key Concept
Tamoxifen acts as an estrogen agonist on the endometrium, increasing the risk of endometrial cancer; therefore, postmenopausal bleeding in these patients requires prompt endometrial biopsy.